Who are Perfuse Therapeutics's investors?

Perfuse Therapeutics's investors include Access Biotechnology, Catalio Capital Management, LP, Hatteras Venture Partners, LAV, Lilly Asia Ventures, OrbiMed, Hatteras.

How much funding has Perfuse Therapeutics raised?

Perfuse Therapeutics has disclosed $11M raised across 2 rounds.

Where is Perfuse Therapeutics headquartered?

Perfuse Therapeutics is headquartered in San Francisco, US.

Perfuse Therapeutics

San Francisco, US · Founded 2018 · Delaware corporation · 9 employees on LinkedIn · 7 known investors

Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy. The company aims to reduce blindness caused by these conditions.

Biotech Medical Devices

Founders & leadership

Board

Christy ShafferBoard director

Chau KhuonginBoard directorPartner at OrbiMed

Sevgi Gurkan in 𝕏Founder, President and CEOVenture Partner at OrbiMed

Investors · 7

Access BiotechnologyNew York City

Catalio Capital Management, LPNew York

Hatteras Venture PartnersResearch Triangle · $500K – $4M

LAVHong Kong · $5M – $15M

Lilly Asia VenturesHong Kongvia Hongbo Lu · board

OrbiMedNew York · $1M – $75Mvia Chau Khuong · board

HatterasreportedRaleigh

Reported raises · per SEC filings

Form D private placements

$11M disclosed across 2 rounds · 2019–2020

▶$9MraisedJul 2020 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Hongbo LuDirector
Christy ShafferDirector
Chau KhuongDirector
Sevgi GurkanExecutive Officer, Director, Promoter
Dan BeckerDirector
Jerry CagleDirector

Offering amount: $39M
Amount sold: $9M
First sale: Jul 2020
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedApr 2019 · 6 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Christy ShafferDirector
Chau KhuongDirector
Sevgi GurkanExecutive Officer, Director, Promoter

Offering amount: $4M
Amount sold: $2M
First sale: Mar 2019
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Ois8 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

Companies competing with Perfuse Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Bayer acquires Hatteras-backed Perfuse Therapeutics for up to $2.45B - Triangle Business Journalbizjournals.com · Jun 2026

Bayer dips toes back into pharma M&A to buy Perfuse Therapeuticsendpoints.news · May 2026

Frequently asked questions

What does Perfuse Therapeutics do?: Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy. The company aims to reduce blindness caused by these conditions.
Who are Perfuse Therapeutics's investors?: Perfuse Therapeutics's investors include Access Biotechnology, Catalio Capital Management, LP, Hatteras Venture Partners, LAV, Lilly Asia Ventures, OrbiMed, Hatteras.
How much funding has Perfuse Therapeutics raised?: Perfuse Therapeutics has disclosed $11M raised across 2 rounds.
Where is Perfuse Therapeutics headquartered?: Perfuse Therapeutics is headquartered in San Francisco, US.